Screener
Merck & Co. MRK Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $16.61B+5.1% | $16.29B+4.9% | $16.4B+5.0% | $17.28B+3.7% | $15.81B-1.9% | ||
| $4.4B+23.6% | $4.2B+22.7% | $5.55B+45.0% | $3.86B-5.5% | $3.56B-5.0% | ||
| $12.21B-0.3% | $12.09B-0.2% | $10.85B-8.0% | $13.42B+6.7% | $12.25B-1.0% | ||
| 73.5%-4.0pp | 74.2%-3.7pp | 66.2%-9.3pp | 77.7%+2.2pp | 77.5%+0.7pp | ||
| $9.74B+141% | $12.59B+248% | $3.89B-15.2% | $4.23B-27.8% | $4.05B+15.7% | ||
| $2.9B+9.6% | $2.7B+5.8% | $2.9B+1.2% | $2.63B-3.6% | $2.65B-3.3% | ||
| -$99M-1,514% | —— | —— | —— | $7M— | ||
| -$683M-114% | -$3.53B-160% | $3.42B-18.0% | $6.75B+64.9% | $5B-16.8% | ||
| $654M+14.5% | $709M-13.3% | $458M+7.5% | $958M+3.1% | $571M+4.8% | ||
| -$1.34B-130% | -$4.24B-183% | $2.96B-20.8% | $5.79B+83.2% | $4.43B-18.8% | ||
| -8%-36.0pp | -26%-58.7pp | 18.1%-5.9pp | 33.5%+14.5pp | 28%-5.8pp | ||
| -$0.54-131% | -$1.72-186% | $1.20-18.9% | $2.32+87.1% | $1.76-17.8% | ||
| -$84M-102% | -$2.95B-146% | $4.91B+4.7% | $7.28B+56.7% | $5.52B-15.4% | ||
| -0.5%-35.4pp | -18.1%-59.4pp | 30%-0.1pp | 42.1%+14.2pp | 34.9%-5.6pp | ||
| -$683M-114% | -$3.53B-160% | $3.42B-18.0% | $6.75B+64.9% | $5B-16.8% |
FAQ
- What is Merck & Co.'s revenue?
- Merck & Co. (MRK) generated $66.6B in revenue over the trailing twelve months, up 4.6% year over year.
- Is Merck & Co. profitable?
- Merck & Co. reported $3.2B in net income over the trailing twelve months, a 4.8% net margin.
- What is Merck & Co.'s earnings per share?
- Merck & Co.'s diluted EPS over the trailing twelve months is $1.26.
- Where does Merck & Co.'s income statement data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
